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Abstract
Background: Periodontitis (PD) has been reported to be associated with rheumatoid arthritis (RA). Porphyromonas
gingivalis (P. gingivalis) is a gram-negative anaerobic bacterium that is recognized as one of the major pathogenic
organisms in PD and is the only bacterium known to express peptidylarginine deiminase (PAD). Antibody against
human α-enolase (ENO1) is one of the autoantibodies in RA. ENO1 is a highly conserved protein, and could be a
candidate molecule for molecular mimicry between bacterial and human proteins. In the present study, we
measured serum antibody against P. gingivalis and human ENO1 in patients with RA and investigated their
association with the severity of PD or disease activity of RA.
Methods: Two hundred, forty-eight patients with RA and 85 age- and sex-matched healthy controls were
evaluated by rheumatologic and periodontal examinations. The serum levels of anti-P. gingivalis and anti-ENO1
antibodies were measured by an enzyme-linked immunosorbent assay (ELISA).
Results: Patients with RA had significantly higher levels of anti-P. gingivalis and anti-ENO1 antibody titers than
the controls (p = 0.002 and 0.0001, respectively). Anti-P. gingivalis antibody titers significantly correlated with
anti-ENO1 antibody titers in RA patients (r = 0.30, p < 0.0001). There were significant correlations between anti-P.
gingivalis antibody titers and the gingival index (GI), probing pocket depth (PPD), bleeding on probing (BOP)
and clinical attachment level (CAL) (p = 0.038, 0.004, 0.004 and 0.002, respectively) in RA. Anti-P. gingivalis
antibody titers were not correlated with disease activity score 28 (DAS28) or anti-CCP titer. However, anti-ENO1
antibody titers were significantly correlated not only with the periodontal indices, such as PPD, BOP, and CAL
(p = 0.013, 0.023 and 0.017, respectively), but also RA clinical characteristics, such as DAS28, anti-CCP titer, and
ESR (p = 0.009, 0.015 and 0.001, respectively).
Conclusion: Anti-P. gingivalis and anti-ENO1 antibody titers were correlated with the severity of PD in RA. Anti-ENO1
antibody titers, but not anti-P. gingivalis antibody titers, were further associated with RA disease activity.
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Background
Rheumatoid arthritis (RA) is chronic inflammatory auto-
immune disease characterized by persistent synovitis,
systemic inflammation, production of autoantibodies,
and bone destruction of joints. RA is more frequent
among women than men (3:1) and its prevalence is 0.5-
1.0 % in the adult population [1–3]. The etiology of RA
remains unknown, but genetic (including HLA-DRB1)
and environmental factors, such as smoking [4–6] and
infection [7–9], play a considerable role in disease sus-
ceptibility [10]. Periodontitis (PD) is one of the most
common chronic disorders of infectious origin with a
prevalence of 10-60 % in adults [11]. PD is caused by a
chronic infection of twenty different bacterial species, of
which Porphyromonas gingivalis (P. gingivalis) is the
most common. A large number of clinical studies have
shown an increased frequency of PD in patients with RA
as compared to individuals without RA [12–15]. One re-
port indicated that the incidence of RA in patients with
PD is a 3.95 % compared to a 1 % prevalence in the gen-
eral population [16]. RA and PD share several genetic
risk factors, such as HLA-DR4-subtypes 0401, 0404,
0405, 0408 [17] and environmental factors such as
smoking [18, 19], and both diseases are characterized by
chronic self-sustaining inflammation [20]. These results
suggest that there could be a positive association of RA
with PD, an infectious disease initiated by oral anaerobic
bacteria. It has been hypothesized that this association
may be based on the capacity of P. gingivalis, the major
etiological agent of PD, which express a peptidylarginine
deiminase (PAD), an enzyme that catalyzes the trans-
formation of arginine to citrulline [21]. P. gingivalis
PADs (PPAD) are capable of citrullinating an endogen-
ous or human protein [22], thereby creating systemic
immunogens that contain epitopes against which anti-
citrullinated protein antibodies (ACPAs) could be raised
[21]. The correlation between anti-P. gingivalis titers
and periodontal indices, such as PPD and CAL, has been
reported in previous studies [23–25]. In contrast, no cor-
relation has been shown between anti-P. gingivalis and
RA disease activity score 28 (DAS28) [25].
The antibody against human α-enolase (ENO1) is the
autoantibody reported in 6-66 % of RA patients [26–29].
ENO1 is a highly conserved protein and could be a can-
didate for molecular mimicry between bacterial and hu-
man host proteins [30]. There is evidence of homology
and cross-reactivity between the enolase of P. gingivalis
and its human origin [9, 31, 32]. Endogenous citrulli-
nated enolases have been reported to be abundant in P.
gingivalis [33]. There has been no report on the associ-
ation of anti-ENO1 and periodontitis or RA disease ac-
tivity. In this study, we investigated serum antibody
responses to P. gingivalis and human ENO1 in patients
with RA compared to controls. Then, we examined
whether anti-P. gingivalis and anti-ENO1 antibodies are




This study was approved by the ethics committee of Seoul
National University Hospital. RA patients (n = 248) were
enrolled at the Rheumatology Clinic at the Seoul National
University Hospital from May 2011 to February 2012 and
satisfied the 1987 American College of Rheumatology
classification criteria of RA [34]. The non-arthritic controls
(n = 85) were age- and sex-matched volunteers in a
3:1 ratio. The institutional review board and ethics
committee approved the protocol (H-1103-151-357), and
written informed consent was obtained from each patient
before study enrollment.
Clinical assessment
We conducted a prospective, cross-sectional study com-
paring RA patients and non-arthritic controls. Patients
underwent interviews to determine socio-demographic
data, medical history, and comorbidities. In RA patients,
clinical parameters including 68 tender joint count (TJC),
66 swollen joint count (SJC), and the patient’s global as-
sessment of disease activity on a visual analogue scale of
100 mm was evaluated. Joint count was performed by a
single rheumatologist (IAC) to minimize interobserver
variability. Disease activity score 28 (DAS28) was calculated
as follows [35, 36]; 0:56 ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ28 tender joint countð Þp þ
0:28 ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ28 swollen joint countð Þp þ 0:70 Ln erythrocyteð
sedimentation rateÞ  1:08þ 0:16.
RA disease duration, morning stiffness, erythrocyte
sedimentation rate (ESR), rheumatoid factor (RF), anti-
cyclic citrullinated peptide (CCP) antibody, and the
presence of erosive changes on X-rays of joints were
evaluated when serum samples were obtained.
In all subjects, the number of teeth (0 - 28, 3rd molars
excluded) was checked. Subjects who had 15 or more
teeth were evaluated with a dental exam and checked for
anti-P. gingivalis and anti-ENO1 antibodies. Two period-
ontologists (JK and YMK) who had been trained for the
periodontal index for more than two years in the same
clinic performed dental exam. The plaque index (PI) was
used as a marker of dental hygiene and graded as 1, 2,
and 3 at three buccal points and one lingual point in
each tooth [37]. Mean values of a maximum of 112
points were used, and higher PI represented poorer den-
tal hygiene. Gingival index (GI), probing pocket depth
(PPD), bleeding on probing (BOP), and clinical attach-
ment level (CAL) were evaluated as indices of periodon-
titis. GI was graded as 1, 2, and 3 at three buccal points
and one lingual point in each tooth. Mean values of a
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maximum of 112 points were used and higher index rep-
resented greater gingival inflammation [38]. PPD was
measured by a 15 mm-University of North Carolina
(UNC) probe in mm scale and higher index scores rep-
resented more severe structural changes; values over
4 mm were considered to be a pathologic condition.
BOP was checked as positive/negative, coded as 1/0, and
positive BOP represented an early sign of inflammation.
The mean value of each tooth was presented in percent-
age. CAL was taken as the distance from the cementoe-
namel junction (CEJ) to the base of the probable crevice.
It was calculated as sum of PPD and gingival recession
measured with the 15 mm-UNC probe in mm scale. It was
regarded as a practical index of periodontitis. Periodontitis
was further defined as slight (CAL 1–2 mm), moderate
(CAL 3–4 mm), and severe (CAL ≥5 mm) according to
American Academy of Periodontology 2004 classification
[39]. PPD, BOP, and CAL were checked at three buccal
points and three lingual points in each tooth and the mean
value of a possible maximum 168 points was used.
Antibody to P. gingivalis
The P. gingivalis strain FDC381 was grown in brain
heart infusion (BHI) broth (Difco, Detroit, MI) supple-
mented with hemin (5 μg/ml), vitamin K (0.5 μg/ml),
and cysteine (0.05 %). Cultures were performed under
anaerobic conditions (GasPak-EZ anaerobe container
system, Becton Dickinson Microbiology systems, MD,
USA) at 37 °C for 3 days. After removal of the media,
the cells were washed with phosphate-buffered saline
(PBS) three times, and then treated with 3 % formalde-
hyde as a fixative. After centrifugation, P. gingivalis cells
were washed with 50 mM sodium carbonate coating
buffer (pH 9.6) and then the number of P. gingivalis cells
was determined by spectrophotometer.
Each well of the 96-well microtiter plate (NUNC,
Roskilde, Denmark) was coated with 1x107 cells/well of
P. gingivalis cells in 50 mM sodium carbonate coating
buffer (pH 9.6) overnight at 4 °C. After washing three
times with PBS containing 0.05 % Tween20 (PBST,
pH 7.4) and blocking with PBS containing 2 % bovine
serum albumin (BSA), two-fold serial dilutions of RA
patients and control sera (first dilution, 1:200) were
added to the plate and the bound human IgG was de-
tected with HRP-conjugated, anti-human IgG antibodies
(Millipore, Billerica, MA, USA, 1/6,000 dilution), followed
by a developer containing TMB (KPL, Gaithersburg, MD).
The anti-P. gingivalis titer was defined as the inverse value
of the largest serial dilution for which detectable antibody
was observed.
Antibody to ENO1
Each well of the 96-well microtiter plate (NUNC,
Roskilde, Denmark) was coated with 1 μg/ml of human
ENO1 recombinant protein (Prospec, Ness-Ziona, Israel)
in 50 mM sodium carbonate coating buffer (pH 9.6) over-
night at 4 °C. After washing three times with PBST, and
blocking with PBS containing 2 % BSA, two-fold serial di-
lutions of RA patients and control sera (first dilution
1:200) were added to the plate and the bound human IgG
was detected with HRP-conjugated, anti-human IgG anti-
bodies (Millipore, 1/6,000 dilution) followed by a developer
containing TMB (KPL, Gaithersburg, MD). The anti-
ENO1 titer was defined as the inverse value of the largest
serial dilution for which detectable antibody was observed.
Serum RF and anti-CCP antibody
The values of serum RF were measured by the immunotur-
bidimetry method (Roche, Swiss), and anti-CCP antibody
titer was measured by chemiluminescent microparticle im-
munoassay (Abbott, USA) according to the manufacturer’s
instructions. Anti-CCP antibody titer over 5 international
unit (IU)/mL was considered as positive.
Statistical analyses
Differences in demographic and clinical parameters were
assessed by Mann–Whitney U tests for the comparison
Table 1 Demographic and periodontal characteristics of
patients with RA and healthy controls
Parameter RA Healthy controls p value
(n = 248) (n = 85)
Age (years, mean ± SE) 60.1 ± 0.7 59.13 ± 1.3 0.512
Female (n, %) 218 (87.9) 74 (87.1) 0.995
Smoking statusa
Current (%) 5 (2.1) 4 (4.7) 0.241
Former (%) 9 (3.8) 4 (4.7) 0.746
Never (%) 224 (94.1) 77 (90.6) 0.228
Severity of periodontitis
Slight (%) 88 (35.5) 57 (67.1) <0.0001†
Moderate (%) 153 (61.7) 28 (32.9)
Severe (%) 7 (2.8) 0 (0)
Number of remaining teeth
(mean ± SE)
25.3 ± 0.2 25.9 ± 0.3 0.063
Periodontal indices
Plaque index (PI) 0.85 ± 0.03 0.69 ± 0.03 0.014
Gingival index (GI) 0.51 ± 0.03 0.14 ± 0.02 <0.0001
Probing pocket depth (PPD) 20.42 ± 0.98 11.69 ± 1.00 <0.0001
Bleeding on probing (BOP) 1.97 ± 0.02 1.74 ± 0.02 <0.0001
Clinical attachment level (CAL) 3.25 ± 0.05 2.89 ± 0.05 <0.0001
RA, rheumatoid arthritis; SE, standard error; slight periodontitis, clinical attachment
loss 1–2 mm; moderate periodontitis, clinical attachment loss 3–4 mm; severe
periodontitis, clinical attachment loss ≥ 5 mm by the American Academy of
Periodontology 2004 classification
aSmoking status of 10 RA patients could not be obtained
†p value by chi-square test (slight vs. moderate and severe)
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of continuous variables, and chi-square or Fisher’s exact
test for categorical variables. Serum levels of antibody to
P. gingivalis and ENO1 between the RA and control
groups were compared by non-parametric Mann–
Whitney U tests.
The correlations between serum antibody to P. gingi-
valis or ENO1 with RA clinical characteristics or
periodontal indices were examined by determining
Spearman correlation coefficients, as appropriate. Mul-
tiple logistic regression models were used to compare
titers of antibodies to P. gingivalis and ENO1 between
RA patients and controls, adjusting for age, sex, and
smoking status. All reported p values were two-sided
and p <0.05 was considered to indicate statistical signifi-
cance. Analysis was performed by using IBM SPSS 19.0
and GraphPad Prism 5.
Results
Demographic and periodontal characteristics of the
study participants are summarized in Table 1. There
were no significant differences in age, sex, smoking
status, and the number of remaining teeth between
the RA and control groups. However, RA patients
had higher levels of clinical periodontal indices such
as PI (mean ± SE, 0.85 ± 0.03 vs. 0.69 ± 0.03, p = 0.014
by Mann–Whitney test), GI (0.51 ± 0.03 vs. 0.14 ± 0.02,
p < 0.0001), PPD (20.42 ± 0.98 vs. 11.69 ± 1.00, p < 0.0001),
BOP (1.97 ± 0.02 vs. 1.74 ± 0.02, p < 0.0001), and CAL
(3.25 ± 0.05 vs. 2.89 ± 0.05, p < 0.0001) compared to the
controls (Table 1). A higher prevalence of moderate and
severe PD was observed in RA patients compared with
control subjects (p < 0.0001 by chi-square test; slight vs.
moderate to severe).
The serum antibody titers to P. gingivalis (mean ± SE,
34,427 ± 3,510 vs. 18,479 ± 1,428, p = 0.003 by Mann–
Whitney test) and ENO1 (2,473 ± 87.97 vs. 2,072 ± 167.4,
p < 0.0001) were significantly higher in patients with RA
compared to control subjects (Fig. 1). The differences
in anti-P. gingivalis or anti-ENO1 antibody titers be-
tween patients with RA and control subjects remained
statistically significant after adjustments for age, sex
and smoking status (p = 0.002 and 0.032, respectively).
Anti-P. gingivalis antibody titers significantly corre-
lated with anti-ENO1 antibody titers in RA patients
(r = 0.30, p < 0.0001 by Spearman test, Fig. 2).
We analyzed the association between anti-P. gingivalis
or anti-ENO1 antibody titers and periodontal indices or
RA clinical characteristics. Anti-P. gingivalis antibody ti-
ters correlated with values of periodontal indices such as
GI (r = 0.13, p = 0.038 by Spearman test), PPD (r = 0.18,
p = 0.004), BOP (r = 0.18, p = 0.004), and CAL (r = 0.19,
p = 0.002) in RA (Table 2). However, anti-P. gingivalis
antibody titers did not significantly correlate with RA
clinical characteristics including DAS28, RF and anti-
CCP titer but correlated with ESR (r = 0.16, p = 0.011 by
Spearman test, Table 3).
Serum anti-ENO1 antibody titers showed statistically
significant correlations with values of PD indices such as
PPD (r = 0.16, p = 0.013 by Spearman test), BOP (r = 0.14,
p = 0.023), and CAL (r = 0.15, p = 0.017) in RA (Table 2).
In addition, anti-ENO1 antibody titers correlated with RA
clinical characteristics such as DAS28 (r = 0.17, p = 0.009
by Spearman test), ESR (r = 0.21, p = 0.001), and anti-CCP
Fig. 1 Serum antibody titers to Porphyromonas gingivalis (a) and α-enolase (b) in RA patients and healthy controls. * p < 0.003, ** p < 0.0001 by
Mann-Whitney U-test; bars represent mean. P. gingivalis, Porphyromonas gingivalis; ENO1, α-enolase
Fig. 2 Correlation between anti-P. gingivalis and anti-ENO1 antibody
titers in RA patients. r = 0.30, p < 0.0001 by Spearman test.
P. gingivalis, Porphyromonas gingivalis; ENO1, α-enolase
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antibody titer (r = 0.17, p = 0.015) in RA patients (Table 3).
There was no correlation of anti-P. gingivalis or anti-
ENO1 and periodontal indices in the healthy controls.
Discussion
The association between RA and PD has been reported
in clinical studies [12–15, 40, 41] and a population-
based study [42]. A large number of clinical studies have
shown an increased frequency of PD in patients with RA
as compared to individuals without RA. Also in our
study population, a higher prevalence of moderate and
severe PD was observed in RA patients compared with
non-RA control subjects. We showed significantly ele-
vated antibody responses to P. gingivalis and ENO1 in
RA patients compared to controls. These findings are
consistent with the results of previous reports on anti-P.
gingivalis [43, 44] and anti-ENO1 [26, 27]. Anti-P. gingi-
valis antibody titers significantly correlated with anti-
ENO1 antibody titers in RA patients. To exclude the
confounding effect by PD status, we subdivided subjects
into slight PD and moderate PD depending on the se-
verity of PD. Serum anti-P. gingivalis antibody titer
was not different between slight PD and moderate PD
subgroup in non-RA controls (p = 0.8736). Similarly,
anti-ENO1 antibody titer was not different between
slight PD and moderate PD subgroup in non-RA con-
trols (p = 0.2578). But in RA patients group, serum
anti-P. gingivalis (p = 0.039) and anti-ENO1 (p = 0.0147)
antibody titer were higher in moderate PD subgroup than
slight PD subgroup (Additional file 1: Figure S1). In RA pa-
tients, anti-P. gingivalis antibody titers correlated with peri-
odontal destruction represented as PPD and CAL as
described in previous studies [23–25]. Moreover, in the
present study the anti-P. gingivalis antibody titer correlated
with gingival inflammation indices, such as GI and BOP as
well. However, anti-P. gingivalis antibody titers did not cor-
relate with RA disease activity. Previous studies have
shown that antibodies to P. gingivalis are associated with
ACPAs, such as anti-CCP antibody in patients with RA
[45, 46]. However, antibodies against P. gingivalis in sero-
positive arthralgia patients were not shown to predict the
development of rheumatoid arthritis [45]. In our cohort,
titers of anti-P. gingivalis antibody were not correlated with
the titers of anti-CCP antibodies.
Anti-ENO1 antibody titers showed a similarly signifi-
cant correlation with PPD, BOP, (reflecting gingival in-
flammation) and CAL (periodontal destruction) in RA
patients. In addition, anti-ENO1 antibody titers corre-
lated with RA disease activities, such as DAS28, ESR,
and anti-CCP titer (p = 0.009, 0.001, and 0.015, respect-
ively) in RA patients. Fisher et al. reported that there
were trends towards higher C-reactive protein (CRP),
DAS28 (CRP) and also greater use of methotrexate in
the anti-citrullinated α-enolase peptide 1 (CEP-1)+/
CCP2+ subset than in the anti-CEP-1-/CCP2+ subset in
one cohort (Norfolk Arthritis Register cohort, p = 0.08)
[47]. We measured the serum antibody against whole
ENO1 protein, but not against citrullinated peptide. The
Table 2 Correlation between titers of anti-P. gingivalis or anti-ENO1 antibody and periodontal indices in patients with RA and controls
Antibody Group PI GI PPD BOP CAL
Anti-P. gingivalis RA r 0.05 0.13 0.18 0.18 0.19
p value 0.423 0.038 0.004 0.004 0.002
Control r −0.10 −0.02 −0.07 0.04 −0.06
p value 0.360 0.845 0.760 0.741 0.610
Anti-ENO1 RA r 0.10 0.06 0.16 0.14 0.15
p value 0.106 0.361 0.013 0.023 0.017
Control r 0.05 −0.04 −0.03 −0.001 −0.12
p value 0.676 0.724 0.757 0.992 0.279
P. gingivalis Porphyromonas gingivalis, ENO1 α-enolase, PI plaque index, GI gingival index, PPD probing pocket depth, BOP bleeding on probing, CAL clinical
attachment level
Table 3 Correlation between titers of anti-P. gingivalis or anti-ENO1 antibody and clinical characteristics of RA
Antibody DAS28 Duration of morning stiffness ESR RF titer Anti-CCP titer
Anti-P. gingivalis r 0.10 −0.01 0.16 0.08 0.08
p value 0.143 0.937 0.011 0.216 0.250
Anti-ENO1 r 0.17 0.02 0.21 0.13 0.17
p value 0.009 0.793 0.001 0.052 0.015
P. gingivalis Porphyromonas gingivalis, ENO1 α-enolase, DAS28 disease activity score 28, ESR erythrocyte sedimentation rate, RF rheumatoid factor, CCP cyclic
citrullinated peptide
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correlation with anti-ENO1 and anti-CCP antibody titers
suggests that patients with anti-ENO1 antibodies might
have antibodies against citrullinated ENO1 due to epi-
tope spreading. Anti-ENO1 antibody titers were signifi-
cantly higher in RA patients with anti-CCP antibodies
than patients without anti-CCP antibodies (p = 0.037 by
Mann–Whitney test, data not shown). Evidence of
cross-reactive immune responses in vivo was previously
reported in an animal model, in which immunization of
DR4 transgenic mice with P. gingivalis enolase, both the
citrullinated and uncitrullinated forms, caused rapid-
onset arthritis [32]. P. gingivalis enolase and human
ENO1 share 51.4 % amino-acid homology, and 82 %
homology at the 17-amino acid immunodominant re-
gions [9, 32]. It was suggested that P. gingivalis may have
a role in breaking tolerance to human ENO1 [9, 31, 32].
Therefore, elevated anti-ENO1 titers in RA may be due
to a cross-reactive immune response to P. gingivalis
enolase. Antibodies against ENO1 have been found in a
variety of autoimmune and inflammatory diseases,
including RA (6-66 %), systemic lupus erythematosus
(19-80 %), mixed cryoglobulinemia (32-64 %), systemic
sclerosis (15-30 %), anti-neutrophil cytoplasmic antibody
(ANCA)-positive vasculitides (37 %), Behcet’s disease
(38-45 %), autoimmune hepatitis (32-56 %), inflamma-
tory bowel disease (10-18 %), and Hashimoto’s thyroid-
itis (6-83 %) [46]. Anti-ENO1 antibodies were reported
to contribute to the perpetuation of synovial inflamma-
tion in RA by stimulating monocytes and macrophages
to produce increased amounts of proinflammatory medi-
ators, such as TNF-α, IL-1α/β, IFN-γ, and PGE2 via the
p38 mitogen activated protein kinase and NF-kB path-
ways [48]. Our result, that anti-ENO1 is correlated with
disease activity, is consistent with those findings.
There are several limitations in our study. Patients
with less than 15 teeth or ongoing dental treatment were
excluded in the evaluation of periodontitis in order to
calculate exact periodontal indices. Therefore, patients
with most severe periodontitis might be excluded in our
analysis.
Study population in this study has Asian genetic back-
grounds, limiting generalizability of our results. How-
ever, this population also has a unique strength that
most subjects in both RA and control group was a
never-smoker. Smoking is a powerful environmental fac-
tor for RA and is known to induce PAD secretion with
inflammatory conditions in the lungs, contributing to
the breakdown of immune tolerance to citrullinated epi-
topes [4–6]. It is also a major risk factor for PD [18, 19],
suggesting a common pathogenic mechanism links the
two diseases and being expected to be a major con-
founder of the study investigating the relation between
PD with RA. Low smoking rate of our study population
may be appropriate to explain substantial number of
non-smokers still developing rheumatoid arthritis and
supports the role of P. gingivalis and anti-ENO1 in RA,
not necessarily linked to smoking. According to the fifth
Korea National Health and Nutrition Examination
Survey (KNHANES V-3), current smokers in Korean
female, stratified by age were 7.9 % in their fifties, and
1.6 % in their sixties, not irrelevant from the results of
this study [49].
We also did not match the proportion of smokers
when recruiting non-arthritis controls and this could in-
fluence the severity of periodontitis. However, there was
no statistically significant difference in smoking status
between the RA and control groups.
We evaluated anti-P. gingivalis antibody and anti-
ENO1 antibody in RA with PD. We showed that anti-P.
gingivalis was associated with the severity of PD in RA
but not with RA disease activities or titers of anti-CCP
antibody. Anti-ENO1 antibodies were correlated with
severity of PD and disease activities in RA.
Conclusion
Anti-P. gingivalis antibodies and anti-ENO1 antibodies
were higher in RA patients than in controls. Anti-P. gin-
givalis antibodies correlated with PD parameters in RA
patients, but not with RA disease activity. Anti-ENO1
antibodies correlated with not only the periodontal indi-
ces but also RA disease activity in RA patients.
Additional file
Additional file 1: Figure S1. Titers of anti-P. gingivalis (A) and anti-ENO1
antibody (B) according to PD severity in healthy control (HC) and RA patients
(Figure not shown in the manuscript). (PDF 210 kb)
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